Ramco Pharm Competitors

We're transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet. For more information, visit www.astrazeneca.com. Community Guidelines: bit.ly/2MgAcio

Pharco Pharmaceuticals Co is a company that operates in the Pharmaceuticals industry. It employs 1-5 people and has $0M-$1M of revenue. The company is headquartered in Egypt.

Amoun established its third state-of-the-art factory (Amoun Pharmaceutical Co.) - designed by John Brown Co. in Chicago following all FDA requirements – and is today considered to be one of the largest and most modern pharmaceutical factories in the Middle East and Africa. Amoun has five branches in Egypt which between them, cover all major sales territories: Two branches in Cairo to cover, Amoun's the region of Greater Cairo, one branch in Mansoura to serve the Delta region, one branch in Alexandria to serve Alexandria, Behira, Kafr El-Sheikh and Matrouh Governorates, and one branch in Assuit to serve Upper Egypt, starting from Menia to Aswan Governorates. Since its establishment in 1985objective was, and still is, to supply the pharmaceutical market with high quality products. Amoun is considered to be one of the largest companies in the field of producing human and veterinary pharmaceutical products and food supplements; covering most of the pharmaceutical groups, including 144 items, which cover more than 264 products of different pharmaceutical forms and concentrations These pharmaceuticals take the form of capsules, tablets, dry syrups, powders, effervescents, syrups, solutions, drops, creams, suppositories, sprays, as well as sterile products such as ampoules, vials, sterile eye drops and eye ointments. Amoun’s veterinary products include 20 names covering 30 products of different forms and concentrations. Due to its prestigious reputation as a leading pharmaceutical manufacturer in Egypt, Amoun produces a number of products under licence from international pharmaceutical companies such as Merck (Germany), Rowa Wagner (Germany), Leurquin (France), and Guerbet (France) for diagnostic injectables. Our strategic plan aims to achieve the production of 110 million packages of different pharmaceutical forms amounting to approximately L.E. 780 million by 2009, and approximately 300 million packages amounting to (+/-) L.E. 2 billion by 2015.